Immunogenic cell death-related signature predicts prognosis and immunotherapy efficacy in bladder cancer.

ABSTRACT:

Background

Immunogenic cell death (ICD) has been verified as a modality of regulated cell death (RCD). Bladder cancer (BC) is a common malignant tumor and ranks tenth in the incidence of global tumor epidemiology. We conducted this study to understand the relationship between ICD and BC and benefit clinical practice.

Methods

Transcriptome and clinical profiling, mutational data of patients were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database. BC patients were divided into ICD-high and -low risk subgroups via consensus clusters. Functional enrichment, somatic mutation analysis, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to explore the potential mechanism. An ICD-related risk signature was cons

SUBMITTER: Guo L 

PROVIDER: S-EPMC11651764 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature